Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Incyte, Hengrui In 'Biggest Ever' China Pharma Out-Licensing Deal

This article was originally published in Scrip

Executive Summary

In an alliance that illustrates the growing attractiveness of rising innovative R&D capabilities at selected Chinese pharma firms, the US oncology-focused company Incyte Corp. has acquired development and commercialization rights in most global markets to SHR-1210, a PD-1-targeting antibody developed by Jiangsu Hengrui Medicine Co. Ltd.

Advertisement

Related Content

Hengrui Pursues Innovation Through New $100m US Spinoff
Immuno-Oncology's Next Wave: Key Targets And Emerging Players

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register